To date,the coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has determined 399,600,607 cases and 5,757,562 deaths worldwide.COVID-19 is a serious threat to human ...To date,the coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has determined 399,600,607 cases and 5,757,562 deaths worldwide.COVID-19 is a serious threat to human health globally.The World Health Organization(WHO)has declared COVID-19 pandemic a major public health emergency.Vaccination is the most effective and economical intervention for controlling the spread of epidemics,and consequently saving lives and protecting the health of the population.Various techniques have been employed in the development of COVID-19 vaccines.Among these,the COVID-19 messenger RNA(mRNA)vaccine has been drawing increasing attention owing to its great application prospects and advantages,which include short development cycle,easy industrialization,simple production process,flexibility to respond to new variants,and the capacity to induce better immune response.This review summarizes current knowledge on the structural characteristics,antigen design strategies,delivery systems,industrialization potential,quality control,latest clinical trials and real-world data of COVID-19 mRNA vaccines as well as mRNA technology.Current challenges and future directions in the development of preventive mRNA vaccines for major infectious diseases are also discussed.展开更多
Dear Editor An optimal vaccination program that can elicit Iong-lasting humoral and cellular immune response is key to Iong-term prevention of coronavirus disease 2019(COVID-19).Multiple variants of severe acute respi...Dear Editor An optimal vaccination program that can elicit Iong-lasting humoral and cellular immune response is key to Iong-term prevention of coronavirus disease 2019(COVID-19).Multiple variants of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)continue to emerge.The neutralizing capacities of available COVID-19 vaccines against these variants have declined.^(1) In such a scenario,heterologous prime-boost programs for COVID-19 vaccines have attracted considerable interest.展开更多
文摘To date,the coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has determined 399,600,607 cases and 5,757,562 deaths worldwide.COVID-19 is a serious threat to human health globally.The World Health Organization(WHO)has declared COVID-19 pandemic a major public health emergency.Vaccination is the most effective and economical intervention for controlling the spread of epidemics,and consequently saving lives and protecting the health of the population.Various techniques have been employed in the development of COVID-19 vaccines.Among these,the COVID-19 messenger RNA(mRNA)vaccine has been drawing increasing attention owing to its great application prospects and advantages,which include short development cycle,easy industrialization,simple production process,flexibility to respond to new variants,and the capacity to induce better immune response.This review summarizes current knowledge on the structural characteristics,antigen design strategies,delivery systems,industrialization potential,quality control,latest clinical trials and real-world data of COVID-19 mRNA vaccines as well as mRNA technology.Current challenges and future directions in the development of preventive mRNA vaccines for major infectious diseases are also discussed.
文摘Dear Editor An optimal vaccination program that can elicit Iong-lasting humoral and cellular immune response is key to Iong-term prevention of coronavirus disease 2019(COVID-19).Multiple variants of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)continue to emerge.The neutralizing capacities of available COVID-19 vaccines against these variants have declined.^(1) In such a scenario,heterologous prime-boost programs for COVID-19 vaccines have attracted considerable interest.
